Company / R&D Expense
Organon & Co. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$366.0M
FY2025
5-year range
$220.0M / $528.0M
FY2021-FY2025
Trend
-22.0%
vs FY2024
Sector context
#47 of 210
Health Care
What the data says
Organon & Co.'s r&d expense of $366M is higher than 78% of companies in the Health Care sector (FY2025). Declined from $528M to $366M over the past 2 years.
Based on SEC 10-K filings.
$366M in FY2025 with a 5-year CAGR of +11.8%. Top quartile in the Health Care sector.
Declined from $528M to $366M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- +11.8%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 210This company $366.0M Sector average $644.0M
▼
-43.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.8%, indicating consistent growth.
- In FY2025, r&d expense decreased 22.0% year-over-year.
- Ranks #47 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $366.0M | -22.0% |
| FY2024 | $469.0M | -11.2% |
| FY2023 | $528.0M | +12.1% |
| FY2022 | $471.0M | +114.1% |
| FY2021 | $220.0M | +4.8% |
| FY2020 | $210.0M | -4.5% |
| FY2019 | $220.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026